Laidlaw analyst Yale Jen downgraded Alaunos Therapeutics to Hold from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TCRT:
- Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)
- ZIOPHARM Oncology trading resumes
- Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
- ZIOPHARM Oncology trading halted, news pending
- TCRT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
